HC Biologics’ Post

I am happy to share that our research team in Aprin Sama Farmed company, has developed a new method for the synthesis of Technetium (99mTc) tilmanocept, a  radiopharmaceutical diagnostic imaging agent used to determine lymph nodes which may be draining from tumors, This radiodiagnostic agent assist doctors in locating lymph nodes for removal during surgery without removing and affecting the healthy lymphs. For further information, see the news in Mehrnews https://lnkd.in/dhQpHbNc TV7%D8%AF%DB%8C%D9%88%D8%AF%D8%A7%D8%B1%D9%88%DB%8C-%D8%AA%D8%AD%D8%B1%DB%8C%D9%85%DB%8C #Tilmanocept #Aprin Sama Farmed #Technetium

MEETING REPORTER talks with Jinsong Ni, Ph.D. founder and Chief Executive Officer of Cloudbreak Pharma, talks about pioneering first-in-class treatments for eye conditions such as #pterygium, #myopia, and #presbyopia. With four products currently in phase two and three clinical trials, this video highlights their flagship therapy CBT-001 for pterygium, an effort to move away from surgery and towards early intervention drug therapy. #ophthalmology, #eyesurgery

Setrons Setrons are drugs that act as serotonin receptor antagonists, specifically targeting the 5-HT3 receptors. These receptors are located in the central and peripheral nervous systems and play a key role in nausea and vomiting pathways. By blocking these receptors, setrons such as ondansetron, granisetron, and palonosetron, are effective in preventing and treating nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. Here, we review some of the key details you need to know about this drug class. #pharmacology #medicine #pharmacy #setrons

Setrons are drugs that act as serotonin receptor antagonists, specifically targeting the 5-HT3 receptors. These receptors are located in the central and peripheral nervous systems and play a key role in nausea and vomiting pathways. ☑️By blocking these receptors, setrons such as ondansetron, granisetron, and palonosetron, are effective in preventing and treating nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. ☑️Here, we review some of the key details you need to know about this drug class. #emesis #vomiting #pharmacology #medicine #pharmacy #setrons

NEW RESEARCH ALERT! Crystal Research Associates released a 48-page EIO on NeXtGen Biologics, Inc. (Closely Held), a closely held medical device company that holds a suite of patents for extracellular matrix (ECM) platform technology derived from the axolotl, a rare paedomorphic salamander closely related to the tiger salamander. Leveraging the Company’s innovative biotechnology, NeXtGen Biologics, Inc. is seeking to unravel the mysteries of regeneration and scar-free healing using the ECM of the axolotl, as this species is capable of regenerating organs and complex tissues (including its nervous system). The Company is currently developing platform solutions to address and enhance the treatment of various intricate conditions found in wound care, general surgery, trauma, plastic surgery, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology. NeXtGen’s first FDA-cleared device, NeoMatriX® Wound Matrix, is indicated for partial and full thickness wounds, pressure venous diabetic and chronic vascular ulcers, surgical wounds, trauma wounds, Mohs surgery, and burns. NeoMatriX is provided as sheets in various sizes for placement on wound beds to help manage the wound environment. Check out our report to learn more about the Company. | https://bit.ly/3LreZjL #NeXtGenBiologics #NeoMatriXWoundMatrix #ExtracellularMatrix #Axolotl #ChronicVascularUlcers #SurgicalWounds #TraumaWounds #MohsSurgery #PartialAndFullThicknessWounds

NEW RESEARCH ALERT! Crystal Research Associates released a 48-page EIO on NeXtGen Biologics, Inc. (Closely Held), a closely held medical device company that holds a suite of patents for extracellular matrix (ECM) platform technology derived from the axolotl, a rare paedomorphic salamander closely related to the tiger salamander. Leveraging the Company’s innovative biotechnology, NeXtGen Biologics, Inc. is seeking to unravel the mysteries of regeneration and scar-free healing using the ECM of the axolotl, as this species is capable of regenerating organs and complex tissues (including its nervous system). The Company is currently developing platform solutions to address and enhance the treatment of various intricate conditions found in wound care, general surgery, trauma, plastic surgery, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology. NeXtGen’s first FDA-cleared device, NeoMatriX® Wound Matrix, is indicated for partial and full thickness wounds, pressure venous diabetic and chronic vascular ulcers, surgical wounds, trauma wounds, Mohs surgery, and burns. NeoMatriX is provided as sheets in various sizes for placement on wound beds to help manage the wound environment. Check out our report to learn more about the Company. | https://bit.ly/3LreZjL #NeXtGenBiologics #NeoMatriXWoundMatrix #ExtracellularMatrix #Axolotl #ChronicVascularUlcers #SurgicalWounds #TraumaWounds #MohsSurgery #PartialAndFullThicknessWounds

Increasing Rates of Bowel Resection Surgery for Stricturing Crohn’s Disease in the Biologic Era In this nationwide study using NIS, the authors investigated longitudinal trends in bowel resection rates for obstruction, a surrogate for stricturing disease, and overall bowel resection rates in those hospitalized with CD in the era of biologics. While overall CD-related resection rates in the United States have decreased since 1998, consistent with prior literature, the study revealed a rise in resection for stricturing disease, constituting nearly 30% of all CD-related bowel resection surgeries in 2020.

The “Global Spinal Implants Market by Product (Devices (Thoracic, Cervical, Interbody Fusion, Spinal Non-Fusion), Biologics, Stimulators), Application (VCF, Spinal Decompression, Fusion, Non-Fusion), Surgery (Open, MIS), Region & Customer Unmet Needs – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. The global spinal implants market is projected to reach USD 14.3 billion by 2028 from USD 11.2 billion in 2023, growing at a CAGR of 5.0%. Find the report here: https://lnkd.in/gJQ5MNBX

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHGVIDEO: Faricimab shows greater reduction in hard exudates in patients with DME

🌟 Check out this insightful article from the Review of Ophthalmology, "What’s on the Horizon for Keratoconus?" featuring our very own EpiSmart! 🔬 Our innovative epithelium-on cross-linking system is highlighted for its groundbreaking approach in Phase III FDA trials. With a focus on minimally invasive treatment, EpiSmart is poised to change the landscape for keratoconus patients. 🚀 #Keratoconus #Ophthalmology #EpiSmart #EyeHealth #MedicalInnovation #EpionTherapeutics